Clinical trials

Only want trials near your city that fit you? Get alerts

Disease

Country

Status

Phase

Reset

265 trials

NCT06564038
Recruiting
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
Phase 1/2 · Australia, China, Czechia, Germany, Denmark, Spain, France, United Kingdom, Italy, Japan, South Korea, Taiwan, United States · 59 sites
Registry update: 28 Oct 2026
NCT06697184
Recruiting
A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
Phase 1/2 · Australia, Brazil, China, Spain, France, United Kingdom, United States · 25 sites
Registry update: 26 Oct 2026
NCT06834529
Recruiting
CAR2219 CAR-T Cells for the Treatment of R/R B Cell Leukemia and Lymphoma
Phase 1/2 · China · 1 site
Registry update: 19 Feb 2025
NCT06890494
Recruiting
Clinical Study on the Safety and Efficacy of BiTE-EV in Relapsed/Refractory Acute B-Cell Leukemia
Early phase 1 · China · 1 site
Registry update: 10 Mar 2026
NCT06588478
Recruiting
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Phase 2 · Australia, Belgium, Canada, Czechia, Germany, Denmark, Spain, France, United Kingdom, Greece, Hungary, Italy, South Korea, Poland, Romania, Slovakia, United States · 134 sites
Registry update: 4 Nov 2026
NCT06208735
Recruiting
CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies
Phase 1 · Canada · 7 sites
Registry update: 14 Oct 2026
2023-510147-37-00
Recruiting
Acalabrutinib Monotherapy vs Investigator’s Choice of Treatment in Patients with Chronic Lymphocytic Leukaemia and Moderate to Severe Cardiac Impairment
Phase 4 · Czechia, Spain, Italy, Poland · 14 sites
Registry update: 28 Oct 2026
NCT06466122
Recruiting
Pirtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients With CLL or SLL Resistant to Covalent BTKi
Phase 2 · United States · 1 site
Registry update: 19 Feb 2026
NCT06398457
Recruiting
Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Bone Marrow or Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
Early phase 1 · United States · 1 site
Registry update: 5 Oct 2026
NCT06542250
Recruiting
A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
Phase 1/2 · Australia, Canada, China, Germany, Denmark, Spain, France, Italy, Japan, United States · 30 sites
Registry update: 30 Sept 2026
2023-510173-34-00
Recruiting
A long-term follow-up study for patients treated with Galapagos CAR T cell therapies
Phase 3 · Belgium, Spain, Finland, Netherlands · 11 sites
Registry update: 11 Sept 2026
NCT06364423
Recruiting
Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias
Phase 1/2 · United States · 1 site
Registry update: 16 Oct 2026
2023-504647-14-00
Recruiting
A multicenter, phase 2 randomized, open label study to evaluate the efficacy and security of zanubrutinib in combination with obinutuzumab in previously untreated patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) (GELLC-10-ZANUBIO)
Phase 2 · Spain · 20 sites
Registry update: 14 Jul 2026
NCT06544785
Recruiting
Zanubrutinib With Obinutuzumab in Untreated Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase 2 · Spain · 19 sites
Registry update: 25 Jun 2026
NCT06428019
Recruiting
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Phase 3 · Australia, Spain, France, United Kingdom, Greece, Puerto Rico, Serbia, Taiwan, United States · 70 sites
Registry update: 9 Apr 2026
Conflicting statuses (not updated in the registry for 7 months)
NCT06395441
Recruiting
Wisconsin Ginseng for Decreasing Cancer Related Fatigue
Phase 3 · United States · 15 sites
Registry update: 20 Oct 2026
NCT06013423
Recruiting
Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
Phase 2 · United States · 1 site
Registry update: 26 Oct 2026
NCT06059391
Recruiting
CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
Phase 2 · United States · 3 sites
Registry update: 23 Oct 2026
2023-508423-13-00
Recruiting
AVO-CLL: a phase III multicenter, randomized, open-label, clinical trial comparing efficacy and safety of acalabrutinib in combination with obinutuzumab versus venetoclax in combination with obinutuzumab in the first-line treatment of newly diagnosed patients with chronic lymphocytic leukemia
Phase 3 · Poland · 7 sites
Registry update: 18 Jul 2025
NCT07145411
Recruiting
HPC Offered for PRESERVE Expansion
Not applicable · United States · 5 sites
Registry update: 6 Nov 2026

Ordered by registry start date. Freshness and sponsorship never change the order.